<DOC>
	<DOCNO>NCT00771888</DOCNO>
	<brief_summary>Positive data originate two polycystic liver patient treat somatostatin analogue , show volume reduction 38.3 % 14.9 % . These two patient complicate polycystic liver therapeutic option available . Patients participate LOCKCYST trial able benefit active treatment . Participants actively treat 24 week .</brief_summary>
	<brief_title>Open-Label Extension LOCKCYST Trial</brief_title>
	<detailed_description>van Keimpema L , de Man RA , Drenth JP . Somatostatin analogues reduce liver volume polycystic liver disease . Gut 2008 September ; 57 ( 9 ) :1338-9 .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Cysts</mesh_term>
	<mesh_term>Hepatomegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<criteria>Participated LOCKCYST trial 18 yrsof age Multiple cysts &gt; 20 Cooperating patient Is willing able comply study drug regimen study requirement . Willingness give write informed consent Use oral anticonceptives estrogen suppletion Females pregnant breastfeed History evidence chronic pulmonary disease associate functional limitation History severe cardiac disease ( eg , NYHA Functional Class III IV , myocardial infarction within 6 month , ventricular tachyarrhythmias require ongoing treatment , unstable angina significant cardiovascular disease ) . In addition , patient document presumed coronary artery disease cerebrovascular disease enrol . History evidence severe illness condition would make patient , opinion investigator , unsuitable study Symptomatic gallstone ( lanreotide decrease gall bladder volume ) Renal failure require hemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>